Menard Didier, Madji Nestor, Manirakiza Alexandre, Djalle Djibrine, Koula Max Roger, Talarmin Antoine
Pasteur Institute of Bangui Central African Republic.
Am J Trop Med Hyg. 2005 May;72(5):581-5.
This paper reports a two-phase study in Bangui, Central African Republic (CAR): first, we assessed the clinical efficacy to chloroquine (CQ), sulfadoxine-pyrimethamine (SP), and amodiaquine (AQ), then we tested the efficacy of two combinations: CQ + SP and AQ + SP. We used the standard 14-day WHO 2001 protocol to compare therapeutic responses in children under 5 years of age with acute uncomplicated Plasmodium falciparum malaria in Bangui between February 2002 and March 2004. The overall treatment failure rates with CQ, AQ, SP, CQ + SP, and AQ + SP were 40.9%, 20.0%, 22.8%, 7.2%, and 0%. These findings suggest that the Ministry of Health should recommend an interim policy with AQ + SP combination as the first-line antimalarial drug in Bangui until best alternative treatments like artemisinin-based combination therapies (ACTs) become available at low prices in the CAR.
首先，我们评估了氯喹（CQ）、磺胺多辛-乙胺嘧啶（SP）和阿莫地喹（AQ）的临床疗效，然后我们测试了两种联合用药方案的疗效：CQ+SP和AQ+SP。我们采用世界卫生组织2001年标准的14天方案，比较了2002年2月至2004年3月期间班吉5岁以下急性非复杂性恶性疟原虫疟疾儿童的治疗反应。CQ、AQ、SP、CQ+SP和AQ+SP的总体治疗失败率分别为40.9%、20.0%、22.8%、7.2%和零。这些研究结果表明，在基于青蒿素的联合疗法（ACTs）在中非共和国以低价可得之前，卫生部应推荐一项临时政策，将AQ+SP联合用药方案作为班吉的一线抗疟药物。
